Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
Raba Thapa,1 Nhukesh Maharjan,2 Govinda Paudyal11Vitreo-retinal Service, Tilganga Institute of Ophthalmology, 2Research Department, Tilganga Institute of Ophthalmology, Kathmandu, NepalPurpose: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following...
Guardado en:
Autores principales: | Thapa R, Maharjan N, Paudyal G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/520b706664a74fc6a3ab4b182338a817 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir M, et al.
Publicado: (2011) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce G, et al.
Publicado: (2014) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008) -
Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion
por: Ito Y, et al.
Publicado: (2015) -
Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
por: Eltutar K, et al.
Publicado: (2013)